目的：系统评价托吡酯预防偏头痛的效果。方法：运用Cochrane系统评价方法，检索PubMed（1990～2009）和CNKI数据库（1990～2009），筛选吡托吡酯预防偏头痛的随机对照试验（randomized controlled triale,RCT），并用RevMan5.0软件进行统计分析。结果：共初检出75篇文献，经筛选最终纳入7篇RCT进行分析，共2083例患者。Meta分析结果显示，安慰剂组与托吡酯组之间偏头痛的发作频率减少值比较，差异有统计学意义（Z=7.46， P<0.01）。结论：本系统评价结果显示，托吡酯比安慰剂更能减少偏头痛的发作频率。但由于本系统评价纳入的随机对照试验数目不多，有必要开展更多设计严谨，大样本、多中心的随机对照试验来确证这种趋势。

Objective To evaluate the efficacy of topiramate on preventing migraine attacks. MethodsPubmed (1990 to 2009) and CNKI (1990 to 2009) were searched. Randomized controlled trials (RCTs) were identified and the data were analyzed by RevMan5.0 software. ResultsSeven RCTs from 75 articles met the inclusion criteria. In total, the data from 2 083 patients were performed by Meta analysis. There was significant difference in the reduction of migraine frequency between topiramate group and placebo group (Z=7.46， P<0.01). ConclusionTopiramate might decrease the frequency of migraine attack. However, since the conclusions are based on limited data, so multi-center large-scale randomized controlled trials with higher quality are needed before drawing a firm conclusion.

［1］Silberstein SD, Neto W, Schmitt J, et al. Topiramate in migraine prevention: results of a large controlled trial［J］. Arch Neurol, 2004, 61(4):490-495.
［2］Stark RJ, Stark CD. Migraine prophylaxis［J］. Med J Aust, 2008, 189(5):283-288.
［3］Storey JR, Calder CS, Hart DE, et al. Topiramate in migraine prevention: a double-blind, placebo-controlled study［J］. Headache, 2001, 41(10):968-975.
［4］Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention: a randomized controlled trial［J］. JAMA, 2004, 291(8):965-973.
［5］潘东波，陈为安，麻瑞龙.托吡酯预防性治疗偏头痛的临床疗效观察［J］. 中国医院药学杂志，2008, 28(12):1010-1012.
PAN Dongbo, CHEN Weian, MA Ruilong. Topiramate in migraine prevention: a double-blind, placebo-controlled study［J］. Chinese Journal of Hospital Pharmacy, 2008, 28(12):1010-1012.
［6］Silberstein SD, Neto W, Schmitt J, et al. Topiramate in migraine prevention: results of a large controlled trial［J］. Arch Neurol, 2004, 61(4):490-495.
［7］Edwards KR, Glantz MJ, Norton JA, et al. Prophylactic treatment of episodic migraine with topiramate: a double-blind, placebocontrolled trial in 30 patients［J］. Cephalalgia, 2000, 20(4):316.
［8］Rapoport A, Mauskop A, Diener HC, et al. Long-term migraine prevention with topiramate: open-label extension of pivotal trials［J］. Headache, 2006, 46(7):1151-1160.
［9］Diener HC, Tfelt-Hansen P, Dahlof C, et al. Topiramate in migraine prophylaxis-results from a placebo-controlled trial with propranolol as an active control［J］. J Neurol, 2004, 251(8):943-950.
［10］Reiter PD, Nickisch J, Merritt G. Efficacy and tolerability of intravenous valproic acid in acute adolescent migraine［J］. Headache, 2005, 45(7):899-903.
［11］Lampl C, Katsarava Z, Diener HC, et al. Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura［J］. J Neurol Neurosurg Psychiatry, 2005, 76(12):1730-1732.
［12］Moskowitz MA.Molecular mechanism of migraine［J］.Rinsho Shinkeigaku, 2008, 48(11):798.
［13］Cady R, Biondi DM. An update on migraine pathophysiology and mechanism-based pharmacotherapeutics for migraine［J］.